Skip to main content
Top
Published in: BMC Pulmonary Medicine 1/2021

Open Access 01-12-2021 | Cystic Fibrosis | Research

A short-term evaluation of a prototype disposable Oscillating Positive Expiratory Pressure (OPEP) device in a cohort of children with cystic fibrosis

Authors: Kevin J. O’Sullivan, Valerie Power, Barry Linnane, Deirdre McGrath, Magdalena Mulligan, Rebecca White, Leonard W. O’Sullivan, Colum P. Dunne

Published in: BMC Pulmonary Medicine | Issue 1/2021

Login to get access

Abstract

Background

Oscillating Positive Expiratory Pressure (OPEP) devices are important adjuncts to airway clearance therapy in patients with cystic fibrosis (CF). Current devices are typically reusable and require daily, or often more frequent, cleaning to prevent risk of infection by acting as reservoirs of potentially pathogenic organisms. In response, a daily disposable OPEP device, the UL-OPEP, was developed to mitigate the risk of contamination and eliminate the burdensome need for cleaning devices.

Methods

A convenience sample of 36 participants, all current OPEP device users, was recruited from a paediatric CF service. For one month, participants replaced their current OPEP device with a novel daily disposable device. Assessment included pre- and post-intervention lung function by spirometry, as well as Lung Clearance Index. Quality of life was assessed using the Cystic Fibrosis Questionnaire – Revised, while user experience was evaluated with a post-study survey.

Results

31 participants completed the study: 18 males; median age 10 years, range 4–16 years. Lung function (mean difference ± SD, %FEV1 = 1.69 ± 11.93; %FVC = 0.58 ± 10.04; FEV1: FVC = 0.01 ± 0.09), LCI (mean difference ± SD, 0.08 ± 1.13), six-minute walk test, and CFQ-R were unchanged post-intervention. Participant-reported experiences of the device were predominantly positive.

Conclusions

The disposable OPEP device maintained patients’ lung function during short term use (≤ 1 month), and was the subject of positive feedback regarding functionality while reducing the risk of airway contamination associated with ineffective cleaning.

Registration

The study was approved as a Clinical Investigation by the Irish Health Products Regulatory Authority (CRN-2209025-CI0085).
Appendix
Available only for authorised users
Literature
1.
go back to reference Kurbatova P, Bessonov N, Volpert V, Tiddens HA, Cornu C, Nony P, et al. Model of mucociliary clearance in cystic fibrosis lungs. J Theor Biol. 2015;372:81–8.CrossRef Kurbatova P, Bessonov N, Volpert V, Tiddens HA, Cornu C, Nony P, et al. Model of mucociliary clearance in cystic fibrosis lungs. J Theor Biol. 2015;372:81–8.CrossRef
2.
go back to reference Cohen-Cymberknoh M, Shoseyov D, Kerem E. Managing cystic fibrosis: strategies that increase life expectancy and improve quality of life. Am J Respir Crit Care Med. 2011;183(11):1463–71.CrossRef Cohen-Cymberknoh M, Shoseyov D, Kerem E. Managing cystic fibrosis: strategies that increase life expectancy and improve quality of life. Am J Respir Crit Care Med. 2011;183(11):1463–71.CrossRef
3.
go back to reference Ewart W. The treatment of bronchiectasis and of chronic bronchial affections by posture and by respiratory exercises. The Lancet. 1901;158(4063):70–2.CrossRef Ewart W. The treatment of bronchiectasis and of chronic bronchial affections by posture and by respiratory exercises. The Lancet. 1901;158(4063):70–2.CrossRef
4.
go back to reference Maxwell M, Redmond A. Comparative trial of manual and mechanical percussion technique with gravity-assisted bronchial drainage in patients with cystic fibrosis. Arch Dis Child. 1979;54(7):542–4.CrossRef Maxwell M, Redmond A. Comparative trial of manual and mechanical percussion technique with gravity-assisted bronchial drainage in patients with cystic fibrosis. Arch Dis Child. 1979;54(7):542–4.CrossRef
5.
go back to reference Myers TR. Positive expiratory pressure and oscillatory positive expiratory pressure therapies. Respir Care. 2007;52(10):1308–27.PubMed Myers TR. Positive expiratory pressure and oscillatory positive expiratory pressure therapies. Respir Care. 2007;52(10):1308–27.PubMed
6.
go back to reference Hess DR. Airway Clearance: Physiology, pharmacology, techniques, and practice. Respir Care. 2007;52(10):1392–6.PubMed Hess DR. Airway Clearance: Physiology, pharmacology, techniques, and practice. Respir Care. 2007;52(10):1392–6.PubMed
7.
go back to reference McIlwaine PM, Wong LT, Peacock D, Davidson AGF. Long-term comparative trial of positive expiratory pressure versus oscillating positive expiratory pressure (flutter) physiotherapy in the treatment of cystic fibrosis. J Pediatrics 2001; w138(6):845–50. McIlwaine PM, Wong LT, Peacock D, Davidson AGF. Long-term comparative trial of positive expiratory pressure versus oscillating positive expiratory pressure (flutter) physiotherapy in the treatment of cystic fibrosis. J Pediatrics 2001; w138(6):845–50.
8.
go back to reference McIlwaine PM, Wong LT, Peacock D, Davidson AGF, of Paediatrics FD. Long-term comparative trial of conventional postural drainage and percussion versus positive expiratory pressure physiotherapy in the treatment of cystic fibrosis. J Pediatrics. 1997;131(4):570–4. McIlwaine PM, Wong LT, Peacock D, Davidson AGF, of Paediatrics FD. Long-term comparative trial of conventional postural drainage and percussion versus positive expiratory pressure physiotherapy in the treatment of cystic fibrosis. J Pediatrics. 1997;131(4):570–4.
9.
go back to reference App EM, Kieselmann R, Reinhardt D, Lindemann H, Dasgupta B, King M, et al. Sputum rheology changes in cystic fibrosis lung disease following two different types of physiotherapy: flutter vs autogenic drainage. Chest. 1998;114(1):171–7.CrossRef App EM, Kieselmann R, Reinhardt D, Lindemann H, Dasgupta B, King M, et al. Sputum rheology changes in cystic fibrosis lung disease following two different types of physiotherapy: flutter vs autogenic drainage. Chest. 1998;114(1):171–7.CrossRef
10.
go back to reference Manor E, Gur M, Geffen Y, Bentur L. Cleaning and infection control of airway clearance devices used by CF patients. Chron Respir Dis. 2017;14(4):370–6.CrossRef Manor E, Gur M, Geffen Y, Bentur L. Cleaning and infection control of airway clearance devices used by CF patients. Chron Respir Dis. 2017;14(4):370–6.CrossRef
11.
go back to reference Linnane B, Collins L, Bussmann N, O’Connell NH, Dunne CP. Medical devices for cystic fibrosis care may be portable reservoirs of potential pathogens. J Hosp Infect. 2017;96(4):397–8.CrossRef Linnane B, Collins L, Bussmann N, O’Connell NH, Dunne CP. Medical devices for cystic fibrosis care may be portable reservoirs of potential pathogens. J Hosp Infect. 2017;96(4):397–8.CrossRef
12.
go back to reference O’Malley CA. Device cleaning and infection control in aerosol therapy. Respir Care. 2015;60(6):917–30.CrossRef O’Malley CA. Device cleaning and infection control in aerosol therapy. Respir Care. 2015;60(6):917–30.CrossRef
13.
go back to reference O’Malley CA. Infection Control in cystic fibrosis: Cohorting, cross-contamination, and the respiratory therapist. Respir Care. 2009;54(5):641–57.CrossRef O’Malley CA. Infection Control in cystic fibrosis: Cohorting, cross-contamination, and the respiratory therapist. Respir Care. 2009;54(5):641–57.CrossRef
14.
go back to reference Saiman L, Siegel JD, LiPuma JJ, Brown RF, Bryson EA, Chambers MJ, et al. Infection prevention and control guideline for cystic fibrosis: 2013 update. Infect Control Hosp Epidemiol. 2014;35(S1):s1–67.CrossRef Saiman L, Siegel JD, LiPuma JJ, Brown RF, Bryson EA, Chambers MJ, et al. Infection prevention and control guideline for cystic fibrosis: 2013 update. Infect Control Hosp Epidemiol. 2014;35(S1):s1–67.CrossRef
15.
go back to reference Farrell P, Joffe S, Foley L, Canny GJ, Mayne P, Rosenberg M. Diagnosis of cystic fibrosis in the Republic of Ireland: epidemiology and costs. Ir Med J. 2007;100(8):557–60.PubMed Farrell P, Joffe S, Foley L, Canny GJ, Mayne P, Rosenberg M. Diagnosis of cystic fibrosis in the Republic of Ireland: epidemiology and costs. Ir Med J. 2007;100(8):557–60.PubMed
16.
go back to reference Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, et al. Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations. Eur Respir J. 2012;40(6):1324–43.CrossRef Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, et al. Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations. Eur Respir J. 2012;40(6):1324–43.CrossRef
17.
go back to reference Andrade Lima C, Dornelas de Andrade A, Campos SL, Brandao DC, Mourato IP, Britto MCA. Six-minute walk test as a determinant of the functional capacity of children and adolescents with cystic fibrosis: A systematic review. Respiratory Med. 2018;137:83–8. Andrade Lima C, Dornelas de Andrade A, Campos SL, Brandao DC, Mourato IP, Britto MCA. Six-minute walk test as a determinant of the functional capacity of children and adolescents with cystic fibrosis: A systematic review. Respiratory Med. 2018;137:83–8.
18.
go back to reference Alpern AN, Brumback LC, Ratjen F, Rosenfeld M, Davis SD, Quittner AL. Initial evaluation of the Parent Cystic Fibrosis Questionnaire—Revised (CFQ-R) in infants and young children. J Cyst Fibros. 2015;14(3):403–11.CrossRef Alpern AN, Brumback LC, Ratjen F, Rosenfeld M, Davis SD, Quittner AL. Initial evaluation of the Parent Cystic Fibrosis Questionnaire—Revised (CFQ-R) in infants and young children. J Cyst Fibros. 2015;14(3):403–11.CrossRef
19.
go back to reference Henry B, Aussage P, Grosskopf C, Goehrs J-M. Development of the Cystic Fibrosis Questionnaire (CFQ) for assessing quality of life in pediatric and adult patients. Qual Life Res. 2003;12(1):63–76.CrossRef Henry B, Aussage P, Grosskopf C, Goehrs J-M. Development of the Cystic Fibrosis Questionnaire (CFQ) for assessing quality of life in pediatric and adult patients. Qual Life Res. 2003;12(1):63–76.CrossRef
20.
go back to reference Modi AC, Quittner AL. Validation of a disease-specific measure of health-related quality of life for children with cystic fibrosis. J Pediatr Psychol. 2003;28(8):535–46.CrossRef Modi AC, Quittner AL. Validation of a disease-specific measure of health-related quality of life for children with cystic fibrosis. J Pediatr Psychol. 2003;28(8):535–46.CrossRef
21.
go back to reference Flegal KM, Cole TJ. Construction of LMS parameters for the Centers for Disease Control and Prevention 2000 growth charts. Natl Health Stat Rep. 2013;63:1–3. Flegal KM, Cole TJ. Construction of LMS parameters for the Centers for Disease Control and Prevention 2000 growth charts. Natl Health Stat Rep. 2013;63:1–3.
22.
go back to reference Stanojevic S, Ratjen F. Physiologic endpoints for clinical studies for cystic fibrosis. J Cyst Fibros. 2016;15(4):416–23.CrossRef Stanojevic S, Ratjen F. Physiologic endpoints for clinical studies for cystic fibrosis. J Cyst Fibros. 2016;15(4):416–23.CrossRef
23.
go back to reference Aurora P, Gustafsson P, Bush A, Lindblad A, Oliver C, Wallis CE, et al. Multiple breath inert gas washout as a measure of ventilation distribution in children with cystic fibrosis. Thorax. 2004;59(12):1068–73.CrossRef Aurora P, Gustafsson P, Bush A, Lindblad A, Oliver C, Wallis CE, et al. Multiple breath inert gas washout as a measure of ventilation distribution in children with cystic fibrosis. Thorax. 2004;59(12):1068–73.CrossRef
24.
go back to reference Gustafsson PM, Aurora P, Lindblad A. Evaluation of ventilation maldistribution as an early indicator of lung disease in children with cystic fibrosis. Eur Respir J. 2003;22(6):972–9.CrossRef Gustafsson PM, Aurora P, Lindblad A. Evaluation of ventilation maldistribution as an early indicator of lung disease in children with cystic fibrosis. Eur Respir J. 2003;22(6):972–9.CrossRef
25.
go back to reference Mulligan M, Collins L, Dunne C, Keane L, Linnane B. Determination of the lung clearance index (LCI) in a paediatric cystic fibrosis cohort. Irish Medical Journal. 2017. Mulligan M, Collins L, Dunne C, Keane L, Linnane B. Determination of the lung clearance index (LCI) in a paediatric cystic fibrosis cohort. Irish Medical Journal. 2017.
26.
go back to reference Svedberg M, Gustafsson PM, Robinson PD, Rosberg M, Lindblad A. Variability of lung clearance index in clinically stable cystic fibrosis lung disease in school age children. J Cyst Fibros. 2018;17(2):236–41.CrossRef Svedberg M, Gustafsson PM, Robinson PD, Rosberg M, Lindblad A. Variability of lung clearance index in clinically stable cystic fibrosis lung disease in school age children. J Cyst Fibros. 2018;17(2):236–41.CrossRef
27.
go back to reference Green K, Kongstad T, Skov M, Buchvald F, Rosthøj S, Marott JL, et al. Variability of monthly nitrogen multiple-breath washout during one year in children with cystic fibrosis. J Cyst Fibros. 2018;17(2):242–8.CrossRef Green K, Kongstad T, Skov M, Buchvald F, Rosthøj S, Marott JL, et al. Variability of monthly nitrogen multiple-breath washout during one year in children with cystic fibrosis. J Cyst Fibros. 2018;17(2):242–8.CrossRef
28.
go back to reference Andrade Lima C, Dornelas de Andrade A, Campos SL, Brandão DC, Mourato IP, Britto MCAd. Six-minute walk test as a determinant of the functional capacity of children and adolescents with cystic fibrosis: A systematic review. Respiratory Med. 2018;137:83–8. Andrade Lima C, Dornelas de Andrade A, Campos SL, Brandão DC, Mourato IP, Britto MCAd. Six-minute walk test as a determinant of the functional capacity of children and adolescents with cystic fibrosis: A systematic review. Respiratory Med. 2018;137:83–8.
29.
go back to reference Li AM, Yin J, Au JT, So HK, Tsang T, Wong E, et al. Standard reference for the six-minute-walk test in healthy children aged 7 to 16 years. Am J Respir Crit Care Med. 2007;176(2):174–80.CrossRef Li AM, Yin J, Au JT, So HK, Tsang T, Wong E, et al. Standard reference for the six-minute-walk test in healthy children aged 7 to 16 years. Am J Respir Crit Care Med. 2007;176(2):174–80.CrossRef
30.
go back to reference O’Sullivan KJ, Collins L, McGrath D, Linnane B, O’Sullivan L, Dunne CP. Children with cystic fibrosis may be performing oscillating positive expiratory pressure therapy incorrectly. Chest. 2018;154(1):231–2.CrossRef O’Sullivan KJ, Collins L, McGrath D, Linnane B, O’Sullivan L, Dunne CP. Children with cystic fibrosis may be performing oscillating positive expiratory pressure therapy incorrectly. Chest. 2018;154(1):231–2.CrossRef
32.
go back to reference Oermann CM, Sockrider MM, Giles D, Sontag MK, Accurso FJ, Castile RG. Comparison of high-frequency chext walloscillation and oscillating positive expiratory pressure in the home management of cystic fibrosis: a pilot study. Pediatric Pulmonol. 2001;32(5):372–7.CrossRef Oermann CM, Sockrider MM, Giles D, Sontag MK, Accurso FJ, Castile RG. Comparison of high-frequency chext walloscillation and oscillating positive expiratory pressure in the home management of cystic fibrosis: a pilot study. Pediatric Pulmonol. 2001;32(5):372–7.CrossRef
Metadata
Title
A short-term evaluation of a prototype disposable Oscillating Positive Expiratory Pressure (OPEP) device in a cohort of children with cystic fibrosis
Authors
Kevin J. O’Sullivan
Valerie Power
Barry Linnane
Deirdre McGrath
Magdalena Mulligan
Rebecca White
Leonard W. O’Sullivan
Colum P. Dunne
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Pulmonary Medicine / Issue 1/2021
Electronic ISSN: 1471-2466
DOI
https://doi.org/10.1186/s12890-021-01525-3

Other articles of this Issue 1/2021

BMC Pulmonary Medicine 1/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine